Home -> Law Blog Directory -> Patent Law Blogs -> Patent Docs
OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patent DocsPhotocure ASA v. Kappos (Fed. Cir. 2010)
By Donald Zuhn, Kevin Noonan, Chris Singer, Sherri Oslick, and Jason Derry
ADVERTISEMENTS
By Andrew Williams -- Last month, in Photocure ASA v. Kappos, the Federal Circuit affirmed the decision by the U.S. District Court for the Eastern District of Virginia that methyl aminolevulinate hydrochloride ("MAL hydrochloride"), brand name Metvixia®, is entitled to patent term extension pursuant to 35 U.S.C. § 156. Metvixia® was approved by the FDA for use in photochemistry or photodynamic therapy to treat actinic keratoses -- precancerous cell growths on the skin. MAL hydrochloride is the methyl ester of aminolevulinic acid hydrochloride ("ALA hydrochloride"). However, MAL hydrochloride received patent protection (U.S. Patent No. 6,034,267 ("the '267 patent")), in part...Full post as published by Patent Docs on June 16, 2010 (boomark / email).
Related Searches
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.

Federal Circuit Upholds Patent Term Extensions in LEVAQUIN and METVIXIA Cases
USPTO Director Kappos Discusses USPTO 2010
Dave Kappos as Next PTO Director
Kappos: Earn Accelerated Examination Rights by Abandoning Worthless Applications








